Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer

Inclusion Criteria: * Signed informed consent form * Performance Status-Eastern Cooperative Oncology Group (ECOG) 0-1 * Histologically or cytologically confirmed gastric cancer * Advanced or recurrent, metastatic disease * At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors ) * Life expectancy of at least 3 months * Target target lesion has not received radiotherapy or non target lesion radiation at least 4 weeks * Haematopoietic and Hepatic status: Absolute neutrophil count \>1.5x109/L,Platelet count \> 100 x 109/L,Hemoglobin at least 9 g/dl,Bilirubin ≤ 1.5 x upper limit of normal (ULN),AST and ALT ≤ 2.5 times ULN(no liver metastasis), ≤5 times ULN(with liver metastasis) * Cardiovascular: Baseline LVEF 50% measured by echocardiography Exclusion Criteria: * Symptomatic brain metastasis * Active or uncontrolled infection * Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2; peripheral neuropathy of grade 2 or greater Symptomatic brain metastasis * Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, uncontrolled hypertension (≥ 180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen * History of other malignancy * Pregnant or lactating women